• Hearing loss affects a considerable number of older adults; one-third of 65-year-olds and half of 75-year-olds suffer from some hearing impairment
• In an increasingly aging society, this could quickly become a public health problem as it is associated with high societal and healthcare costs
• INND continues to disrupt hearing healthcare; committed to providing game-changing hearing technology in a potentially growing market for hearing aids
• InnerScope’s launches its hearing aids on FSAstore.com, HSAstore.com, and WellDeservedHealth.com consumers enrolled in flexible spending accounts (“FSA”), health saving accounts (“HSA”), and employers’ health incentive programs

InnerScope Hearing Technologies (OTC: INND), a hearing health technology company that manufactures, develops, distributes, and sells innovative hearing health-related products, solutions, and treatments, appears poised to enhance the quality of life for around 70 million Americans suffering from hearing-related problems and to contribute to the improvement of their mental and physical well-being. Age-related hearing loss — also called presbycusis — is a common condition in older adults. It is estimated that about one-third of 65-year-olds and half of 75-year-olds suffer from some hearing loss. The condition considerably impacts the quality of life of affected people, hindering their ability to communicate with their environment and function in society (https://ibn.fm/N7eXz). With such a negative impact on their social lives, it comes as no surprise that the disease is linked to a higher incidence of depression, anxiety, and dementia. A National Institute on Deafness and Other Communication Disorders study revealed that more than 11% of adults with hearing loss also suffer from depression, compared with only 5% of the general population (https://ibn.fm/LmcgE). Hearing loss also coexists with higher levels of anxiety and is associated with higher rates of dementia, especially when coupled with visual impairment (https://ibn.fm/phr0L). It is also strongly associated with higher cognitive and physical impairment. Given numerous associated health risks, hearing loss burdens affected individuals, their families, and the economy as it leads to higher healthcare costs. In an increasingly aging society, this is becoming a critical public health concern. Despite a high prevalence of hearing loss, only about one-fifth of people who could benefit from a hearing aid seek intervention, and even fewer take advantage of technology that might help them. This means that there is a large population of patients living with unmet healthcare needs (https://ibn.fm/Uv72J). This is where InnerScope can offer solutions that can change the lives of millions of Americans suffering from hearing loss. As a direct-to-consumer manufacturer, distributor, and retailer of FDA-registered Bluetooth app-controlled self-adjusting hearing aids and personal sound amplifiers products, the Company is poised to empower consumers to take control of their hearing care. InnerScope recently launched its hearing aids and related hearing products on FSAstore.com, HSAstore.com, and WellDeservedHealth.com for the 70 million consumers enrolled in flexible spending accounts (“FSA”), health saving accounts (“HSA”), and employers’ health incentive programs.  InnerScope partnered with the online retailer and industry leader in the U.S. tax-free healthcare market. Moreover, InnerScope’s hearing aids and related hearing products qualify as eligible products for FSA and HSA users and is the only company on the retailers’ websites to offer hearing aids. The Company is committed to bringing hearing healthcare to customers’ homes by providing top-quality, affordable access to hearing aids without the need to see a hearing professional or go to a hearing care clinic. The Company continues to revolutionize the hearing healthcare landscape despite being in the retail hearing device business for over 70 years. By delivering the same quality of medical-grade hearing technology and the same level of expert support at a fraction of the cost of traditional channels, InnerScope strives to remove barriers to hearing healthcare for millions of people suffering from hearing impairment. For more information, visit the company’s website at www.INND.com and the company’s e-commerce website: www.MyHearIQ.com. NOTE TO INVESTORS: The latest news and updates relating to INND are available in the company’s newsroom at https://ibn.fm/INND

• Brain Scientific focused on leveraging AI and ML to detect neurological diseases, aims to create comprehensive database of brain biomarkers to increase diagnosis accuracy
• Brain Scientific positioned to disrupt EEG market with FDA-cleared patented products that provide cost-effective brain imaging in any setting
• Current global EEG device market estimated at $956.1 million with CAGR of 8.7% from 2019 to 2026, expected to reach $1.6 billion by 2026

With more industries embracing artificial intelligence (“AI”) and machine learning (“ML”) than ever before, Brain Scientific (OTCQB: BRSF), a commercial-stage healthcare company, is ahead of the curve in the neurology market with its development of cost-effective next-generation medical devices and software that aim to leverage AI and ML to improve brain diagnostics in the rapidly growing electroencephalogram (“EEG”) market. AI generally refers to human-like intelligence capabilities demonstrated by computers, and ML is a subset of AI that refers to algorithms that “learn” through the use of data. Together, they are being used in healthcare to analyze data sets and make treatment predictions that aim to produce better health outcomes. With a similar goal, BRSF aims to leverage AI and ML to improve diagnostic capability with a database of brain biomarkers that collect data on both normal and abnormal brain information. Brain Scientific’s use of AI and ML is part of its overall market penetration strategy that includes the development of its patented FDA-cleared NeuroCap(TM) and NeuroEEG(TM) devices. With 22 electrodes and 19 active EEG channels, the NeuroCap — a disposable pre-gelled EEG headset — can be used to record EEGs in nearly any setting. The NeuroCap is complimented by the NeuroEEG — a portable clinical-grade wireless EEG amplifier that acquires, records, displays and transmits electrical brain activity. Cost-effective, portable, and easily accessible, both devices together are positioned to profoundly shift the market by offering practitioners an affordable way to diagnose brain-related disorders in a range of locations, including remote clinical research labs, neurology clinics, urgent care clinics, emergency departments, ICUs, assisted living facilities, and nursing homes. According to Grandview Research, the current global EEG device market was estimated at $956.1 million in 2020 and is expected to reach $1.6 billion revenue by 2026 with an anticipated CAGR of 8.7% between 2019-2026 (https://ibn.fm/AYsYg). Along with roughly 150 million people diagnosed with epilepsy, dementia and Alzheimer’s disease globally, BRSF is strongly positioned to capture a significant market share of the demand for low-cost imaging devices across the world. Headquartered in New York, Brain Scientific and its wholly owned subsidiary MemoryMD Inc. were founded in 2015 and went public in 2018. With a focus on developing innovative medical devices and software that disrupt the brain diagnostics market, BRSF is poised to take center stage with solutions that enable medical professionals to cost-effectively diagnose patients with consistency, efficiency and accuracy in virtually any setting. For more information, visit the company’s website at www.BrainScientific.com/Invest-Now. NOTE TO INVESTORS: The latest news and updates relating to BRSF are available in the company’s newsroom at https://ibn.fm/BRSF

• Microdose Psychedelic Insights will host the upcoming DMT Conference on September 9-10th, 2021
• Part of a series of deep dive events looking into various psychoactive and psychedelic substances, the DMT conference will examine the potential of DMT within today’s society
• The conference will play host to a number of keynote presentations and discussions delivered by some of the industry’s leading thinkers and innovators

Microdose Psychedelic Insights (“Microdose”) is set to host their virtual DMT Conference on September 9-10th, 2021. The event will serve as a deep dive into the dynamic field of DMT therapeutics, featuring a number of expert panels and engaging discussions focused on the potential of Dimethyltryptamine (“DMT”) in today’s society. Microdose Psychedelic Insights, a cutting-edge media company focused around promoting content, financial analysis, and engaging events focused around the psychedelics industry, have gained renown for their unique vision towards shifting the global perception around psychedelic medicine through a series of innovative events. Forming part of Microdose’s Molecular Masterclasses conference series, which has previously featured events looking into Ketamine, MDMA, Ibogaine and Functional Mushrooms, the DMT Conference will seek to introduce investors and attendees to a curated group of CEO’s, corporate leaders and scientists who will seek to delve deeper into the intricacies surrounding the DMT universe. This year’s conference will be inaugurated by an introductory talk, delivered by Patrick Moher, CEO of Microdose Psychedelic Insights. The conference will subsequently play host to a series of hour long presentations and keynote addresses exploring different aspects within the psychedelic industry and DMT in particular. Topics which will be covered will include, “Addiction and DMT” delivered by Entheon Biomedical; “Non-Neuropsychiatric Uses for DMT” by PharmaDrug Inc, “DMT Drug Development” from Small Pharma INC; and a keynote presentation by Algernon Pharmaceuticals entitled “DMT – New Hope for Healing the Brain After a Stroke” among various others. In addition, the conference will also feature several other expert speakers, including the likes of Christopher Timmermann-Slater, Andrew Hegle, Paul Van Slyke, Daniel Cohen, Christopher Moreau, Jackie von Salm, Carol Routledge, Brian Jahns, Natan Ponieman, Andrew Hegle Paul Van Slyke, Christopher Timmermann-Slater Peter Rands, Graham Pechenik David Wood, Ruth Chun, Hadas Alterman Rick Strassman MD, Timothy Ko, Brian Jahns, Crystal Carson, Joël Brierre, Max Montrose, Tricia Eastman, Rak Razam, Victoria Wueschner. Microdose’s DMT Conference will be presented in partnership with Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) (FSE: 1XU1), a biotechnology company focused on developing psychedelic medicines to treat addiction, Small Pharma (TSX.V: DMT) a neuropharmaceutical company taking a novel approach to depression drug development, Algernon Pharmaceuticals Inc. (CSE: AGN) a clinical-stage drug development company focused on the disease areas of stroke, idiopathic pulmonary fibrosis (“IPF”) & chronic cough, and COVID-19, and Pharmadrug, a Biotech Company Focused on the R&D of Natural Based Medicines. Additional information about the DMT Conference, as well as details for registration can be found at the DMT Conference website at https://microdose.buzz/pnwmm About Microdose Psychedelic Insights: Microdose Psychedelic Insights is your guide to the psychedelic medicine industry. With a vision to shift the world’s perception of psychedelic medicine, we distribute and create the most compelling content, financial analysis, engaging events, and groundbreaking education to drive the psychedelics industry to the forefront of modern medicine. About Molecular Masterclasses: Our Molecular Masterclasses are a speaker series designed for deep dives into the world’s favourite psychoactive and psychedelic substances. Each event will explore one drug, and feature a curated group of industry experts and thought leaders from around the world. Contact: Microdose Psychedelic Insights kristina@microdose.buzz Media Contact:  InvestorBrandNetwork (“IBN”) Los Angeles, California www.InvestorBrandNetwork.com

• On August 25, FingerMotion held a conference call in which it provided updates on the progress of its Sapientus division, application to uplist to the NASDAQ, and more
• Hosted by FingerMotion CEO Martin Shen, the corporate update also included a review of the Q1 2022 results, which marked the fourth consecutive quarter of record revenue
• FingerMotion received its first comment letter from NASDAQ, to which it responded promptly and efficiently
• The company, in collaboration with its partners, has begun translating products under the Sapientus division into an actual operational pilot
• FNGR will hold an AGM in November

In July last year, FingerMotion (OTCQX: FNGR) launched Sapientus, its Big Data Insights arm and third operational division, built to deliver data-driven insights and solutions for companies and businesses in the insurance and financial services sectors (https://ibn.fm/fMJF6). Since then, the division has grown in many ways. For instance, it witnessed two consecutive quarters of revenue generation during Q4 2021 and Q1 2022 and quarter-over-quarter revenue growth during the latter reporting period (https://ibn.fm/iPz2A). Additionally, earlier this year, FNGR reported an agreement between Sapientus and Pacific Life Re-Insurance to provide cutting-edge behavioral risk analytics for the insurance company (https://ibn.fm/xSnGM). So, what further progress has the division made since then? In an August 25 conference call, whose recording is available on the company’s website (https://ibn.fm/BnQra), FingerMotion CEO Martin Shen sought to answer this question as part of a corporate update aimed at informing shareholders and the general public about FNGR’s progress thus far and outlook for the future. Included in the August 25 update were the strides the Sapientus division has made, progress on the application to uplist on NASDAQ, a review of the Q1 2022 results, and general announcements. Firstly, Martin discussed the Q1 2022 results for the three months ended May 31, 2021. Pleased with all facets of the business as all facets were growing tremendously, he observed that Q1 2022 represented the company’s fourth consecutive quarter of record revenue, having recorded revenue of $6 million. According to Shen, FingerMotion is optimistic that it will be a profitable business “fairly soon” and has set its sights on higher-margin verticals. Regarding its uplist application to the Nasdaq Capital Market, FNGR focused on “getting it right the first time” by meeting most of the objective criteria and parameters. “To further bolster our own confidence, we received our first comment letter from Nasdaq fairly quickly, meaning we had met most of the parameters in the first place,” Shen added. The company brought in an independent advisory firm, which collaborated with its in-house counsel to issue an efficient, fast response to the comment letter. Shen was, however, quick to caution viewers on the need to keep their optimism in check, given that several other hurdles are yet to be surmounted. Still, he expressed his pride in his team’s work so far, further noting the company’s commitment to promptly and efficiently answering all questions NASDAQ’s examiners send. “The launch of Sapietus marked a significant milestone for our journey because we moved away from being a top-up company to this dynamic technology solution provider and allowed us to expand our company and business into insurance and then the wider financial industry in general,” Shen described Sapientus. He continued, “Our distinctive edge and what we do as Sapientus is our ability to integrate all these publicly available data into these proprietary risk matrices with behavioral indicators derived from event-driven or even contextual-based information.” Shen pointed out that Sapientus, which prioritizes privacy protection, uses advanced algorithms to generate distributional statistics and categorical variables agnostic to individual identity. Crucially, though, the data only contains demographic markers. By providing the desired level of customer understanding through behavioral analytics, Sapientus aims to supply actionable intelligence and facilitate the efficient delivery of services to various players within the insurance industry. Working with partners such as Pacific Life Re-Insurance, FingerMotion has begun translating its Sapientus-based products into an actual operational pilot that benefits the service providers and customers alike. For insurance companies, it will provide value, enhance efficiencies, and lower the cost-of-service delivery. At the same time, it will eliminate existing pain points insurance customers had. Shen also outlined future development plans for the Sapientus division. Lastly, FingerMotion announced its AGM scheduled for November and will provide additional updates on this in due course. For more information, visit the company’s website at www.FingerMotion.com. NOTE TO INVESTORS: The latest news and updates relating to FNGR are available in the company’s newsroom at https://ibn.fm/FNGR

Date: September 10-12, 2021 Exhibit Hall Hours Friday, September 10     11:00 AM – 5:00 PM Saturday, September 11    11:00 AM – 5:00 PM Sunday, September 12      10:00 AM – 4:00 PM Hynes Convention Center, Boston MA Onsite Box Office opens at 9:00 am each day Cannabis cultivators, dealers, businesses, and enthusiasts are invited to attend the NECANN, on September 10-12, 2021. Operating since 2014, NECANN events are touted as one of the largest cannabis events on the east coast. The NECANN events attract a huge number of Hemp, MMJ and Cannabis industry professionals in the Northeast to their annual Boston Cannabis Convention. These events are the home base for the New England cannabis industry. The New England Cannabis Convention in Boston offering robust networking, communication and business opportunity for cannabis growers, consumers and business cultivators across the region. The 2019 event was attended by over 9,000 people, which is expected to cross the 10,000 marks this year. With recreational marijuana legal in Massachusetts, the crowds at the event have grown phenomenally. The event is attended by industry stalwarts, thinkers and cannabis leaders who share their insights, business ideas and discuss the future trends of this growing industry. The NECANN offers a wonderful platform to small industries, startups and new cannabis growers and dealers to discover new business prospects and establish ties with eminent cannabis companies and investors. They also learn the latest trends and technologies that can be employed in the cultivation and supply of the cannabis crop. The event offers knowledge and information regarding the latest regulation and taxation laws that are applied to marijuana cultivation and the tools and requisites these cultivators require to get started. They will also get educated about the environmental concerns surrounding the harmful effects of indoor cultivation and how government schemes are necessary to encourage environmental sustainability and energy performance in cannabis cultivation techniques. The event also showcases the Certified Massachusetts Marijuana Responsible Vendor Training course, which is approved by the state of Massachusetts for cannabis dispensary agents and meets the responsible dispensing organization agent training requirements mandated. Attendees can register beforehand for this event as it requires a separate ticket. Small businesses and cultivators must attend this session to gain clarity on the Commonwealth’s cultivation regulations and understand the steps that growers and cannabis advocacy groups are taking to get more businesses up and bring more craft cannabis to patients and other adult consumers. For more details about the event, please visit https://necann.com/2020-boston-2/.

Date: September 13-15, 2021 Venue-The Marriott Marquis Times Square, New York- Virtual only access also available On September 13-15, 2021, the FinovateFall is being held at The Marriott Marquis Times Square, New York. Organizations, financial institutions, fintech industry leaders, and finance influencers are invited to attend the FinovateFall 2021, an event that can also be accessed virtually. The event will be attended by global influencers and thinkers of the finance arena who will share their valuable insights and strategies on the latest global trends. FinovateFall offers a robust platform for the fintech fraternity to establish connections and derive ideas to take their business to the next level. The pandemic has altered the financial landscape with things going digital in a big way. The FinovateFall will benefit fintech professionals and financial institutions alike. At this Fintech conference, attendees can participate in various discussions, attend seminars, and listen to keynotes from industry stalwarts. You could share your perspectives on varied financial topics with peers and other finance heads. Finovate is a global platform that is known to encourage start-ups, tech companies, financial enterprises, regulators, and investors across the globe. A global-level webinar that believes in bringing your enterprise to the center stage, attendees can be a part of live discussions, meetings, live demos given by both startups and established companies, and learn from the insights of experienced fintech professionals. As the situation has still not returned to normal in many parts of the world, Finovate is organizing a physical event that can also be digitally accessed by fintech enthusiasts worldwide. What to Expect In the live demo sessions, each company gets 7 minutes to display its business goals and aspirations on a power-packed main stage in complete transparency. This event gives companies and startups a great chance to showcase their talents amidst fintech heads who might notice their caliber. Attendees can engage with their mentors and find new connections to grow their business network. The FinovateFall is attended by professionals leading the fintech revolution and industry heads with years of experience that they will share in this 3-day global event of the financial technology industry. Connect with us at the FinovateFall to network and collaborate with the most influential people in the fintech sphere. To know more details about the event and the discounts available, please visit https://informaconnect.com/finovatefall/.

Date: September 16-17, 2021 Online Livestream Event – Locations will vary Dynamic Global Events (“DGE”) invites biopharma and medical device industry professionals to join them online September 16-17, 2021, for the 2nd Clinical Trial Agreements Conference. DGE’s first event was held online earlier this year and was focused greatly on the COVID-19 pandemic, the confidentiality of subject data, and the increased use of telemedicine, among other topics. The first event helped industry professionals determine what needed to be considered before entering into a clinical trial agreement. This conference features a distinguished speaking faculty ready to offer the strategies and best practices to guide professionals through the negotiation process toward a successful clinical trial agreement result. Featured speakers during the two-day conference on September 16-17 will include Jeff Odom, Manager, Global Clinical Trial Contracts, Trial Capabilities – Eli Lilly (NYSE: LLY); Donald Louis Joseph Campodonico, Clinical Trials Contracts Officer I – Stanford University School of Medicine; Tracie Carroll, Associate General Counsel – Turning Point Therapeutics (NASDAQ: TPTX); and many others. Each of these speakers will be covering a specific topic area including, but not limited to, the impact of new standard contractual clauses and GDPR, the role of CROs in a clinical trial contract process; the in-depth look at negotiations between sites and sponsors; telemedicine and the role it plays with remote trial agreements; and the global landscape for clinical trial agreements. The Scarritt Group Companies, a company that supports clinical trial solutions, is sponsoring the event. Some of the event partners for the 2nd Clinical Trial Agreements Conference include BioMed Wire, InvestorBrandNetwork, Pharma Marketing Network, MedTube, and many other industry-driven organizations. Online registration for the event is being held by RegFox and can be completed online through DGE’s conference website. The event carried an early bird special (prior to 8/20/2021) ticket price of $996, and standard/on-demand ticket pricing is $1,196. Registration and log-in for the event will take place on September 16, between 8:30 am and 9:00 am EST. The Chairperson’s opening remarks will begin promptly at 9:00 am. For more information, or to see a full list of keynote speakers and partners for the 2nd Clinical Trial Agreements Conference, please visit the event website. To purchase tickets and register for the event, visit https://ibn.fm/O7ryT

• Avricore Health recently announced that screening had begun at 15 select Shoppers Drug Mart Pharmacies
• The company intends to expand its rapid diagnostics to other parts of Canada, as well as the US, UK, and EU
• Avricore aims to use diagnostics to generate data that it can then use to make better decisions and create outcomes
• It hopes to be a tremendous contributor to the critical data pool that is going to make medicines cheaper, more effective, and get to patients quicker

When Avricore Health (TSX.V: AVCR) (OTCQB: AVCRF) signed a master agreement with Shoppers Drug Mart Inc., Canada’s leading pharmacy network, in June 2021, it intended to provide accessible, high-quality diagnostics with real-time data reporting. This, coupled with the support offered by the pharmacy chain, the company noted, would be a powerful combination in the battle against chronic disease, including diabetes and cardiovascular conditions, in Canada (https://ibn.fm/RR2a5) So far, this partnership has been fruitful. In an August 10 update, Avricore announced 15 select Shoppers Drug Mart pharmacies had received the HealthTab(TM) systems, thus heralding the onset of patient testing to those with known conditions associated with pre-diabetes or already identified as diabetic. The systems, which feature the HealthTab-integrated Afinion 2 analyzers by Abbott (NYSE: ABT), aim at offering diagnostic support and pharmacist-led consultation services (https://ibn.fm/hZU1J). Initially, the master agreement stipulated that only 11 Shoppers Drug Mart stores would receive the platform and offer screening services, but the figure has since been updated to 15 locations. This update appears to be in line with Avricore’s goals, given that the company intends to expand its rapid testing to more pharmacies and pharmacy brands across Canada. It is also looking to expand to the US, UK, and EU. Notably, though, diagnostics are only a cog in the company’s ever-rotating wheel. In a podcast interview with Paul Benwell & Associates, Avricore CEO Hector Bremner described the testing as a means to an end (https://ibn.fm/0tTQv). “One of the many things I’ve learned in Covid testing, in particular, is that buying tests or doing testing is not a strategy. The only reason you are testing is to get information. That information is what you are supposed to be focusing on,” Bremner stated. He noted that HealthTab is about obtaining data and using it to make better decisions and create outcomes. It is this data that Avricore also intends to capitalize on as part of its monetization plan, particularly through de-identification. The platform can be used by major drug makers who wish to screen patients with chronic conditions in decentralized clinical trials; these manufacturers would pay depending on the agreed-upon model. In cases where drugs are extremely particular about kidney and heart functions, drug makers can use HealthTab to get the efficacy of the drug right. “So, every time that person [a patient taking such drugs] comes in and picks up their prescription, they should be tested, and their biomarkers should be matched up against what their current prescription level is and that dosage modified. That’s another way a drug maker can have an ongoing program to pay to make sure that their patients are more effectively served,” Bremner explained. By working with a pharmacy network, Avricore also aims to provide contract research organizations (“CROs”) the desired level of engagement with patients. These CROs, which are companies that run clinical trials on behalf of drug makers, can also purchase the de-identified data for their predictive software programs. “We think in the long run, Avricore is going to be a tremendous contributor to that critical data pool that is going to make medicines cheaper, more effective, and get to patients quicker,” Bremner explained. Avricore is a pharmacy service innovator focused on revolutionizing point-of-care data reporting for better patient outcomes. Aiming to become a leading health data company globally, AVCR is utilizing its point-of-care technologies, packaged into HealthTab, within the community of pharmacies. For more information, visit the company’s website at www.AvricoreHealth.com. NOTE TO INVESTORS: The latest news and updates relating to AVCRF are available in the company’s newsroom at https://ibn.fm/AVCRF

• Company’s nonprovisional patent application includes claims to compositions, methods to support certain elements of preclinical and research programs
• Two international patent applications will grant Cybin the right to file future national applications into treaty member jurisdictions
• Cybin portfolio consists of 14 patent filings, 50-plus proprietary molecules, 50-plus preclinical studies and 4 active drug programs

Cybin (NEO: CYBN) (NYSE American: CYBN), a biotechnology company focused on progressing psychedelic therapeutics, is moving forward to progress and strengthen its IP portfolio by filing three patents this month. After receiving an international search report of its May 2021 Patent Cooperation Treaty (“PCT”) application, Cybin filed a U.S. nonprovisional patent application claiming priority to the May 2021 PCT application (https://ibn.fm/MHCO7), and the company also filed two additional international patent applications, bringing the potential to obtain patent coverage in 153 countries (https://ibn.fm/mZ0BL). According to the company, the International Patent Searching (“IPC”) authority provided a written opinion in support of the novelty, inventive steps and industrial applicability to multiple claims within Cybin’s patent filing. As a result, the nonprovisional patent application includes claims to compositions and methods to support certain elements of the company’s preclinical and research programs. “Cybin’s portfolio now consists of 14 patent filings, 50-plus proprietary molecules, 50-plus preclinical studies, and 4 active drug programs targeting major depressive disorder, alcohol use disorder, anxiety and therapy-resistant psychiatric disorders,” said Cybin CEO Doug Drysdale. “We continue to progress our IP portfolio across novel molecules, delivery mechanisms, processes and protocols as we continue to find new and novel discoveries through our preclinical findings, thus expanding and strengthening IP.” The two international patent applications, governed by the PCT, will grant Cybin the right to file future national applications into treaty member jurisdictions, including important potential markets for the company. In addition, the PCTs cover a library of phenethylamine and derivative drug-development candidates and methods of use. One of Cybin’s PCT patent applications is in connection with a group of proprietary compounds identified by the company’s research data as being key for further evaluation toward selection as potential therapeutics. The other PCT application includes claims and disclosures toward several other proprietary novel psychedelic compounds, including compounds with positive research data, meeting the company’s internal research metrics. Cybin believes these applications will further strengthen its proprietary CYB005 program, which is targeting therapy-resistant psychiatric disorders, and will provide compositions for further evaluation in future research programs. Cybin is on a mission to revolutionize mental health care. The company is focused on progressing psychedelic therapeutics by utilizing proprietary drug-discovery platforms, innovative drug-delivery systems, novel formulation approaches and treatment regimens for psychiatric disorders. For more information, visit the company’s website at www.Cybin.com. NOTE TO INVESTORS: The latest news and updates relating to CYBN are available in the company’s newsroom at https://ibn.fm/CYBN

• Company is beginning to deliver vehicles on a grander scale
• IMC anticipates deliveries to individuals, fleets, dealers and government agencies during the second half of the year
• With each step forward, Imperium is seeing its dealer-candidate network of future dealers expand

DSG Global (OTCQB: DSGT) and its automotive division, Imperium Motor Corp. (“IMC”), are taking significant steps forward as they strengthen their position in the growing market for smart new-energy vehicles. Imperium is working with two partners, Skywell Auto and Jonway Automotive Group, to offer 26 EV models for sale at both DSGT California facilities: the Fairfield Experience Center and Palmdale Manufacturing Facility (https://ibn.fm/vESr7). “The company is finally in a position, with increasing production and inventory, regular shipments and proper lines of credit with the various manufacturers, to begin delivering vehicles on a grander scale,” said Imperium Motors CEO Rick Curtis. “The current backlog is being processed, and the company anticipates deliveries to individuals, fleets, dealers and government agencies during the second half of the year.” In addition to its partnerships with Skywell Auto and Jonway Automotive Group, Imperium has received approval in Europe for its ET5 SUV and is expecting homologation in the North American market to soon follow. The company is also ready to deliver its new Rumble Air SS to Canada and is anticipating major exposure from its upcoming automotive shows, including BusCon and the Los Angeles Auto Show, where the company plans on unveiling new models as well as displaying many of its 26 current models. New models expected to be available soon include the popular new Jonway e-FORCE Scooters, which are new on the floor at the Experience Center, and Skywell’s 12-meter EV city bus, which just arrived in Palmdale. Imperium also announced that its Terra trucks are in hand and are undergoing various upgrades and homologation testing. Finally, the division’s D-11 cargo vans and multi-passenger vans, as well as the new Jonway T01 coupes ,are on their way to the Experience Center. With each step forward, Imperium is seeing its dealer-candidate network of future dealers expand. An EV sales and marketing company, IMC is focused on offering a wide variety of affordable vehicles equipped for the North American market with emphasis on great design, a green mindset, and superior performance and functionality. Its line of vehicles will comprise high-speed, mid-speed, and low-speed electric vehicles, including cars, trucks, SUVs, vans, buses and scooters. DSG Global is an emerging global technology company with an array of interconnecting businesses in some of the fastest-growing market sectors. With roots in the golf industry, in which it specializes in fleet management with patented analytics, mobile touch-screen engagement and electric golf carts under the Vantage Tag Systems (“VTS”) brand, the company is moving quickly with road-ready electric vehicles for sale in the third quarter of 2021 through its Imperium Motor Company subsidiary. For more information, visit the company’s website www.DSGTGlobal.com. NOTE TO INVESTORS: The latest news and updates relating to DSGT are available in the company’s newsroom at https://ibn.fm/DSGT